# IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

VANDA PHARMACEUTICALS INC.,

Plaintiff,

V.

C.A. No. 18-651-CFC (Consolidated)

TEVA PHARMACEUTICALS USA, INC., et al.,

Defendants.

# JOINT STIPULATION AND [PROPOSED] ORDER REGARDING SCHEDULE FOR PRETRIAL EXCHANGES

WHEREAS, the Court previously entered a Scheduling Order in the above-captioned action, setting a deadline for Joint Proposed Pretrial Order of February 16, 2022, D.I. 206, 238;

WHEREAS, the parties to the above-captioned actions have negotiated dates for exchange of pretrial documents in order to timely file the Joint Proposed Pretrial Order;

WHEREAS, the proposed schedule for pretrial exchanges does not alter any deadlines set by the Court, D.I. 206, 238;

WHEREAS, the parties have agreed to defer exchanging objections to exhibits as part of the pretrial order and, instead, will provide their objections to exhibits disclosed to the other side pursuant to the procedures in the pretrial order in advance of the use of such exhibits at trial.

NOW THEREFORE,

IT IS HEREBY STIPULATED AND AGREED, by and between the parties to the abovecaptioned action, subject to the approval of the Court, that the schedule for exchanging the Joint Pretrial Order and exhibits thereto is as follows:

Event(s)		Proposed Date
Plaintiff provides:		January 11, 2022
•	Draft of cover pleading for the Joint Proposed Pretrial Order	
•	Ex. 1 – Draft of parties' Joint Statement of Uncontested Facts	
•	Ex. 2 – Plaintiff's draft Statement of Contested Issues of Fact for issues on which Plaintiff bears the burden of proof	
•	Ex. 4 – Plaintiff's draft Statement of Contested Issues of Law for issues on which Plaintiff bears the burden of proof	
•	Ex. 6 – Plaintiff's Witness List	
٠	Ex. 8 – Plaintiff's Deposition Designations	
•	Ex. 10 - Plaintiff's Trial Exhibit List (in excel format)	
Defendants provide:		
•	Ex. 3 – Defendants' draft Statement of Contested Issues of Fact for issues on which Defendants bear the burden of proof	
•	Ex. 5 – Defendants' draft Statement of Contested Issues of Law for issues on which Defendants bear the burden of proof	
•	Ex. 7 – Defendants' Witness List	
•	Ex. 9 – Defendants' Deposition Designations	
•	Ex. 11 - Defendants' Trial Exhibit List (in excel format)	

Event(s)	Proposed Date
Plaintiff provides:	January 21, 2022
<ul> <li>Ex. 2 – Plaintiff's revised Statement of Contested Issues of Fact (responsive to Defendants' Statement of Contested Issues of Fact for issues on which Defendants bear the burden)</li> </ul>	
<ul> <li>Ex. 4 – Plaintiff's revised Statement of Contested Issues of Law (responsive to Defendants' Statement of Contested Issues of Law for issues on which Defendants bear the burden)</li> </ul>	
Defendants provide:	
Revisions to the Joint Proposed Pretrial Order cover pleading	
• Ex. 1 – Revisions to draft of parties' Joint Statement of Uncontested Facts	
• Ex. 3 – Defendants' revised Statement of Contested Issues of Fact (responsive to Plaintiff's Statement of Contested Issues of Fact for issues on which Plaintiff bears the burden)	
<ul> <li>Ex. 5 – Defendants' revised Statement of Contested Issues of Law (responsive to Plaintiff's Statement of Contested Issues of Law for issues on which Plaintiff bears the burden)</li> </ul>	
Exchange topics for motions in limine. Each side is limited to three motions in limine. (D.I. 206 at ¶ 27.)	January 24, 2022
Meet and confer regarding topics for motions in limine, exhibit lists, and other issues regarding Joint Pretrial Order	January 26, 2022

	Event(s)	Proposed Date
Plaintiff provides:		January 31, 2022
•	Ex. 9 – Objections and counter-designations to Defendants' Deposition Designations	
•	Ex. 12 – Joint Trial Exhibit List (in excel format) and copies of exhibits	
•	Ex. 13 – Plaintiff's Brief Statement of Intended Proofs	
•	Ex. 15 – Plaintiff's statement of additional matters	
•	Ex. 17 - Plaintiff's experts' CVs	
•	Ex. 19 – Motion(s) in limine. Each motion in limine may be supported by a maximum of three (3) pages of argument. (D.I. 206 at ¶ 27)	
Defendants provide:		
•	Ex. 8 – Objections and counter-designations to Plaintiff's Deposition Designations	
•	Ex. 14 – Defendants' Brief Statement of Intended Proofs	
•	Ex. 16 - Defendants' statement of additional matters	
•	Ex. 18 - Defendants' experts' CVs	
•	Ex. 20 -Motion(s) in limine. Each motion in limine may be supported by a maximum of three (3) pages of argument. (D.I. 206 at ¶ 27)	

Event(s)	Proposed Date
Plaintiff provides:	February 7, 2022
• Ex. 7 – Plaintiff's objections to Defendants' Witness List	
<ul> <li>Ex. 8 – Plaintiff's objections to Defendants' counter- designations</li> </ul>	
<ul> <li>Ex. 20 – Responsive brief(s) to motion(s) in limine. Each motion in limine may be opposed by a maximum of three (3) pages of argument. (D.I. 206 at ¶ 27)</li> </ul>	
Defendants provide:	
• Ex. 6 – Defendants' objections to Plaintiff's Witness List	
<ul> <li>Ex. 9 – Defendants' objections to Plaintiff's counter- designations</li> </ul>	
<ul> <li>Ex. 19 – Responsive brief(s) to motion(s) in limine. Each motion in limine may be opposed by a maximum of three (3) pages of argument (D.I. 206 at ¶ 27)</li> </ul>	
Plaintiff provides:	February 11, 2022
• Ex. 19 – Reply brief(s) to motion(s) in limine. Reply briefs in support of a motion in limine may be a maximum of one (1) page of argument. (D.I. 206 at ¶ 27)	
Defendants provide:	
• Ex. 20 – Reply brief(s) to motion(s) in limine. Reply briefs in support of a motion in limine may be a maximum of one (1) page of argument. (D.I. 206 at ¶ 27)	
Meet and confer on any outstanding issues.	
File Joint Proposed Pretrial Order	February 16, 2022 (previously set by Court and unchanged)
Objections to exhibits	As set forth in the parties' Joint [Proposed] Pretrial Order

For reference, the Exhibits ("Ex.") that would accompany the Joint Proposed Pretrial Order and are mentioned above include:

- Ex. 1 Joint Statement of Uncontested Facts.
- Ex. 2 Plaintiff's Statement of Contested Issues of Fact.
- Ex. 3 Defendants' Statement of Contested Issues of Fact.
- Ex. 4 Plaintiff's Statement of Contested Issues of Law.
- Ex. 5 Defendants' Statement of Contested Issues of Law.
- Ex. 6 Plaintiff's Witness List (including Defendants' objections).
- Ex. 7 Defendants' Witness List (including Plaintiff's objections).
- Ex. 8 Plaintiff's Deposition Designations (including Defendants' objections and counter-designations; Plaintiff's objections to counter-designations and counter-counter-designations).
- Ex. 9 Defendants' Deposition Designations (including Plaintiff's objections and counter-designations; Defendants' objections to counter-designations and counter-counter-designations).
- Ex. 10 Plaintiff's Trial Exhibit List (PTX) (including Defendants' objections).
- Ex. 11 Defendants' Trial Exhibit List (DTX) (including Plaintiff's objections).
- Ex. 12 Joint Trial Exhibit List (JTX).
- Ex. 13 Plaintiff's Brief Statement of Intended Proofs.
- Ex. 14 Defendants' Brief Statement of Intended Proofs.
- Ex. 15 Plaintiff's Statement of Additional Matters.
- Ex. 16 Defendants' Statement of Additional Matters.
- Ex. 17 Plaintiff's Experts' CVs.
- Ex. 18 Defendants' Experts' CVs.
- Ex. 19 Plaintiff's Motion(s) in Limine, Defendants' Opposition(s), Plaintiff's Reply, and Exhibits Thereto.
- Ex. 20 Defendants' Motion(s) in Limine, Plaintiff's Opposition(s), Defendants' Reply, and Exhibits Thereto.

Dated: January 10, 2022

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

SHAW KELLER LLP

### /s/Derek J. Fahnestock

Karen Jacobs (#2881)
Derek J. Fahnestock (#4705)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
kjacobs@morrisnichols.com
dfahnestock@morrisnichols.com

Attorneys for Plaintiff Vanda Pharmaceuticals Inc.

#### OF COUNSEL:

Nicholas Groombridge
Eric Alan Stone
Josephine Young
Daniel J. Klein
Jennifer Rea Deneault
Michael F. Milea
Jacob M. Berman
PAUL, WEISS, RIFKIND, WHARTON
& GARRISON LLP
1285 Avenue of the Americas
New York, NY 10019
(212) 373-3000

### /s/Karen E. Keller

John W. Shaw (#3362)
Karen E. Keller (#4489)
Nathan R. Hoeschen (#6232)
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
dfry@shawkeller.com
nhoeschen@shawkeller.com

Attorneys for Defendant Teva Pharmaceuticals USA, Inc.

### OF COUNSEL:

J.C. Rozendaal
Deirdre M. Wells
William H. Milliken
Sasha S. Rao
STERNE, KESSLER, GOLDSTEIN
& FOX P.L.L.C.
1100 New York Avenue, N.W., Suite 600
Washington, DC 20005
(202) 772-8747

#### COZEN O'CONNOR

# PHILLIPS, McLaughlin, & Hall

### /s/Thomas Francella

Thomas Francella (#3835) 1201 North Market Street, Suite 1001 Wilmington, DE 19801 (302) 295-2025 tfrancella@cozen.com

Attorneys for Defendants Apotex Inc. and Apotex Corp.

### OF COUNSEL:

Barry P. Golob W. Blake Coblentz Aaron S. Lukas COZEN O'CONNOR 1200 Nineteenth Street N.W. Washington, DC 20036 (202) 912-4800

Keri L. Schaubert COZEN O'CONNOR 3 WTC, 175 Greenwich Street, 55th Fl. New York, NY 10007 (212) 509-9400

### /s/John C. Phillips, Jr.

John C. Phillips, Jr. (#110) David A. Bilson (#4986) 1200 North Broom Street Wilmington, DE 19806 (302) 655-4200 jcp@pmhdelaw.com dab@pmhdelaw.com

Attorneys for Defendants MSN
Pharmaceuticals Inc. and MSN Laboratories
Private Limited

### OF COUNSEL:

Bryce A. Cooper Maureen L. Rurka Reid F. Smith WINSTON & STRAWN LLP 35 West Wacker Drive Chicago, IL 60601 (312) 558-5600

Noorossadat Torabi WINSTON & STRAWN LLP 101 California Street, 35th Fl. San Francisco, CA 94111

##